期刊文献+

T790M突变所致吉非替尼耐药肺腺癌细胞放射敏感性变化及耐药性逆转的研究 被引量:2

Change of Radiosensitivity and Reversal of Drug Resistance in Gefitinib-resistant Lung Adenocarcinoma Cell Caused by T790M Mutation
下载PDF
导出
摘要 目的探讨T790M突变所致吉非替尼耐药肺腺癌细胞株PC-9/GR放射敏感性的变化情况及经射线照射后PC-9/GR吉非替尼耐药的逆转情况。方法选取吉非替尼敏感肺腺癌细胞株PC-9及T790M突变所致吉非替尼继发性耐药肺腺癌细胞株PC-9/GR。应用液相芯片法检测这两种细胞中人第10号染色体缺失的磷酸酶及张力蛋白同源的基因(PTEN)mRNA表达水平;应用免疫印迹法检测这两种细胞中磷酸化哺乳动物雷帕霉素靶蛋白(p-mTOR)、磷酸化蛋白激酶B(p-Akt)、PTEN蛋白表达水平;采用集落形成实验观察射线照射细胞的存活情况;应用四甲基偶氮唑盐(MTT)比色法检测细胞的生长抑制情况。结果 (1)PC-9/GR的PTEN mRNA及其蛋白表达水平均高于PC-9(P<0.05),而p-mTOR、p-Akt蛋白表达水平则低于PC-9(P<0.05)。(2)在不同剂量6 MV X线作用下,PC-9/GR的细胞存活分数(SF)均低于PC-9(P<0.05)。(3)在不同浓度吉非替尼作用下,射线照射的PC-9/GR的生长抑制率均高于未照射的PC-9/GR(P<0.05),半数抑制浓度(IC50)则低于未照射的PC-9/GR(P<0.05)。射线照射的PC-9/GR每一吉非替尼浓度的生长抑制率均高于未经照射的PC-9/GR(P<0.05)。结论在体外实验条件下,肺腺癌细胞株PC-9/GR的放射敏感性较其亲代PC-9升高,射线照射后的PC-9/GR在一定程度上能逆转吉非替尼的耐药。 Objective To investigate the change of radiosensitivity in gefitinib- resistant lung adenocarcinoma cell line PC- 9 /GR caused by T790 M mutation,and the reversal of drug resistance in gefitinib- resistant PC- 9 /GR after X ray irradiation. Methods Gefitinib- sensitive lung adenocarcinoma cell line PC- 9 and T790 M mutation- induced secondary gefitinib- resistant lung adenocarcinoma cell line PC- 9 /GR cell line were selected. Liquid chip method was applied to detect the expression level of PTEN mRNA in the two kinds of cells; Western blotting method was used to detect the expression level of p- mTOR,p- Akt and PTEN proteins; Colony formation assay was carried out to observe the survival situation of the cells which were irradiated by X ray; MTT colorimetric method was used to study the growth inhibition of cells. Results The expression levels of PTEN mRNA and PTEN proteins in PC- 9 /GR were significantly higher than those in PC- 9( P〈0. 05),while the expression levels of p- mTOR and p- Akt in PC- 9 /GR were significantly lower than those in PC- 9( P〈0. 05). With the action of different doses of 6 MV X ray,the survival fraction( SF) of PC- 9 /GR was significantly lower than that of PC- 9( P〈0. 05). With the action of different concentrations of gefitinib,the growth inhibition rate of PC- 9 /GR with irradiation was significantly higher than that of unirradiated PC- 9 /GR( P〈0. 05),and the IC50 values in irradiated PC- 9 /GR were significantly lower than those in non- irradiated PC- 9 /GR( P〈0. 05). In every concentration of gefitinib,the growth inhibition rates of PC- 9 /GR with irradiation were significantly higher than those of unirradiated PC- 9 /GR( P〈0. 05). Conclusion Under the experimental conditions in vitro,the radiosensitivity of lung adenocarcinoma PC- 9 /GR cells is higher than that of its parental PC- 9 cells,and the irradiated PC- 9 /GR cells can reverse gefitinib resistence to some extent.
出处 《中国全科医学》 CAS CSCD 北大核心 2014年第30期3570-3574,共5页 Chinese General Practice
基金 吴阶平医学基金会项目(320.6750.12247)
关键词 肺肿瘤 T790M突变 辐射耐受性 吉非替尼 多药耐药相关蛋白质类 Lung neoplasms T790M mutation Radiation tolerance Gefitinib Multidrug resistance-associated proteins
  • 相关文献

参考文献10

  • 1Nyati MK, Morgan MA, Feng FY, et al. Integration of EGFR inhibitors with radiochemotherapy [ J ]. Nat Ca Rev, 2006, 6 ( 11 ) : 876 - 885.
  • 2Lachyankar MB, Sultana N, Schonhoff CM, et al. A role for nuclear PTEN in neuronal differatlation [ J ]. J Neurosci, 2000, 20 ( 4 ) : 1404 - 1413.
  • 3Hanahan D, Weinberg RA. The hallmarks of cancer [ J ]. Cell, 2000, 100 (1): 57-70.
  • 4Ginn - Pease ME, Eng C. Increased nuclear phosphatase and resin hom- ologue deleted on chromosome 10 is associated with GO - GI in MCF - 7 cells [J]. Cancer.Res, 2003, 63 (2): 282-286.
  • 5Cantley LC. The Phosphoinositide 3 - kinase pathway [ J ]. Science, 2002, 296 (5573) : 1655 - 1657.
  • 6Liang K, Jin W, Knuefermann C, et al. Targeting the phosphatidyli- nositol 3 - kinase/Akt pathway for enhancing breast cancer cells to radio- therapy [J]. Mol Cancer Ther, 2003, 2 (4): 353-360.
  • 7Deorukhkar A, Krishnan S. Targeting inflammatory pathways for tumor radiosensitization [J]. Biochem Pharmacol, 2010, 80 (12) : 1904 -1914.
  • 8Gimm O, Perren A, Weng LP, et al. Differential nuclear and cytoplas- mic expression of PTEN in normal thyroid tissue, and benign and malig- nant epithelial thyroid tumors [ J ]. Am J Pathol, 2000, 156 ( 5 ) : 1693 - 1700.
  • 9Nicholson KM, Anderson NG. The protein kinase B/Akt signaling pathway in human malignancy [J]. Cell Signal, 2002, 14 (5) : 381 -395.
  • 10何臣,徐军.吉非替尼耐药人肺腺癌PC-9/GR细胞株的建立及其生物学特性[J].中国病理生理杂志,2010,26(A10):2017-2017. 被引量:4

共引文献3

同被引文献23

  • 1Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncology . 2010 (2)
  • 2Caicun Zhou,Yi-Long Wu,Gongyan Chen,Jifeng Feng,Xiao-Qing Liu,Changli Wang,Shucai Zhang,Jie Wang,Songwen Zhou,Shengxiang Ren,Shun Lu,Li Zhang,Chengping Hu,Chunhong Hu,Yi Luo,Lei Chen,Ming Ye,Jianan Huang,Xiuyi Zhi,Yiping Zhang,Qingyu Xiu,Jun Ma,Li Zhang,Changxuan You.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J].Lancet Oncology.2011(8)
  • 3Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncology . 2012 (3)
  • 4Helena A. Yu,Camelia S. Sima,James Huang,Stephen B. Solomon,Andreas Rimner,Paul Paik,M. Catherine Pietanza,Christopher G. Azzoli,Naiyer A. Rizvi,Lee M. Krug,Vincent A. Miller,Mark G. Kris,Gregory J. Riely.Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors[J]. Journal of Thoracic Oncology . 2013 (3)
  • 5Andrew J. Weickhardt,Benjamin Scheier,Joseph Malachy Burke,Gregory Gan,Xian Lu,Paul A. Bunn,Dara L. Aisner,Laurie E. Gaspar,Brian D. Kavanagh,Robert C. Doebele,D. Ross Camidge.Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer[J]. Journal of Thoracic Oncology . 2012 (12)
  • 6Bing Han,Xiang Zhou,Rong-Xin Zhang,Wang-Fu Zang,Zhong-Yuan Chen,Huai-Dong Song,Huan-Ying Wan,Cui-Xia Zheng.Mutations of the epidermal growth factor receptor gene in NSCLC patients[J]. Oncology Letters . 2011 (6)
  • 7Chih-Chia Chang,Kwan-Hwa Chi,Shang-Jyh Kao,Pei-Sung Hsu,Yuk-Wah Tsang,Heng-Jui Chang,Yu-Wung Yeh,Yei-San Hsieh,Jiunn-Song Jiang.Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience[J]. Lung Cancer . 2010 (2)
  • 8Jin-Ji Yang,Hua-Jun Chen,Hong-Hong Yan,Xu-Chao Zhang,Qing Zhou,Jian Su,Zhen Wang,Chong-Rui Xu,Yi-Sheng Huang,Bin-Chao Wang,Xue-Ning Yang,Wen-Zhao Zhong,Qiang Nie,Ri-Qiang Liao,Ben-Yuan Jiang,Song Dong,Yi-Long Wu.Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer[J]. Lung Cancer . 2012
  • 9Maemondo Makoto,Inoue Akira,Kobayashi Kunihiko,Sugawara Shunichi,Oizumi Satoshi,Isobe Hiroshi,Gemma Akihiko,Harada Masao,Yoshizawa Hirohisa,Kinoshita Ichiro,Fujita Yuka,Okinaga Shoji,Hirano Haruto,Yoshimori Kozo,Harada Toshiyuki,Ogura Takas.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England Quarterly . 2010
  • 10Meiyan Jiang,Chengrong Zhang,Jin Wang,Jun Chen,Chunmei Xia,Dongshu Du,Na Zhao,Yinxiang Cao,Linlin Shen,Danian Zhu.??Adenosine A 2A R modulates cardiovascular function by activating ERK1/2 signal in the rostral ventrolateral medulla of acute myocardial ischemic rats(J)Life Sciences . 2011 (5)

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部